Matthew Kelsey
Stock Analyst at HC Wainwright & Co.
(2.44)
# 2,410
Out of 5,182 analysts
7
Total ratings
25%
Success rate
58.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Kelsey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Assumes: Buy | $100 | $31.79 | +214.56% | 1 | Jun 2, 2025 | |
| ACXP Acurx Pharmaceuticals | Assumes: Buy | $160 | $1.98 | +7,980.81% | 1 | May 15, 2025 | |
| DBVT DBV Technologies | Maintains: Equal-Weight | $260 → $100 | $19.79 | +405.31% | 5 | Dec 20, 2018 |
Sensei Biotherapeutics
Jun 2, 2025
Assumes: Buy
Price Target: $100
Current: $31.79
Upside: +214.56%
Acurx Pharmaceuticals
May 15, 2025
Assumes: Buy
Price Target: $160
Current: $1.98
Upside: +7,980.81%
DBV Technologies
Dec 20, 2018
Maintains: Equal-Weight
Price Target: $260 → $100
Current: $19.79
Upside: +405.31%